Literature DB >> 9603419

Paracrine and autocrine regulation of vascular endothelial growth factor during tissue differentiation in the quail.

M Aitkenhead1, B Christ, A Eichmann, M Feucht, D J Wilson, J Wilting.   

Abstract

The expression of vascular endothelial growth factor (VEGF) has been described to coincide both temporally and spatially with angiogenesis suggesting a role as a paracrine stimulator of endothelial cells. We have used digoxigenin labelled RNA probes to VEGF and the VEGF receptor-2 (Quek1) to investigate the relationship between VEGF expression and vascular events in quail embryos from day 1 to 13 of incubation. Furthermore, the effect of exogenously applied VEGF was studied in day 4 quail embryos using polyclonal anti-VEGF antibodies. Expression of VEGF mRNA was observed in day 1 and 2 embryos in regions of active angiogenesis and hemangiopoiesis. VEGF mRNA expression was found at high levels in the ventral aspect of the neural tube and Quek1 mRNA expression in the accompanying endothelial cells of day 3 embryos, suggesting a function in brain angiogenesis. However, in the neural tube, thyroid gland and cartilaginous skeleton VEGF mRNA was expressed at least 1 day before the ingrowth of vessels, suggesting that additional mechanisms are involved in control of angiogenesis. This is supported by the observation that application of VEGF165 into the midbrain induced dilatation of perineural vessels, while the intraneural vessels remained almost unaffected. Expression of VEGF mRNA was also observed at high levels in podocytes during all stages, indicative of its importance in glomerular development and function. The results of the present study indicate that as angiogenesis occurred in other tissues and organs (day 13 metanephros, dorsal third of the day 7 neural tube, skeletal muscle, and many mesodermal compartments), there was concurrent paracrine expression of VEGF mRNA and Quek1 mRNA. One noteable exception was the hepatocytes of the developing liver which appeared to remain VEGF-negative throughout the study. However, a small number of endothelial cells within liver sinuses, and additionally within the kidney and the elastic arteries, expressed VEGF mRNA. These results suggest that VEGF may also act as an autocrine mediator of angiogenesis, possibly as a result of localised tissue hypoxia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9603419     DOI: 10.1002/(SICI)1097-0177(199805)212:1<1::AID-AJA1>3.0.CO;2-L

Source DB:  PubMed          Journal:  Dev Dyn        ISSN: 1058-8388            Impact factor:   3.780


  6 in total

Review 1.  Physiology of angiogenesis.

Authors:  H Kurz
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

2.  Quantitative morphodynamics of endothelial cells within confluent cultures in response to fluid shear stress.

Authors:  P Dieterich; M Odenthal-Schnittler; C Mrowietz; M Krämer; L Sasse; H Oberleithner; H J Schnittler
Journal:  Biophys J       Date:  2000-09       Impact factor: 4.033

3.  Neurovascular development uses VEGF-A signaling to regulate blood vessel ingression into the neural tube.

Authors:  Jennifer M James; Cara Gewolb; Victoria L Bautch
Journal:  Development       Date:  2009-01-28       Impact factor: 6.868

4.  VEGF expression is developmentally regulated during human brain angiogenesis.

Authors:  Daniela Virgintino; Mariella Errede; David Robertson; Francesco Girolamo; Antonio Masciandaro; Mirella Bertossi
Journal:  Histochem Cell Biol       Date:  2003-03-11       Impact factor: 4.304

5.  Notochord-derived BMP antagonists inhibit endothelial cell generation and network formation.

Authors:  Michael Bressan; Patricia Davis; John Timmer; Doris Herzlinger; Takashi Mikawa
Journal:  Dev Biol       Date:  2008-11-12       Impact factor: 3.582

6.  Vascular endothelial growth factor modulates skeletal myoblast function.

Authors:  Antonia Germani; Anna Di Carlo; Antonella Mangoni; Stefania Straino; Cristina Giacinti; Paolo Turrini; Paolo Biglioli; Maurizio C Capogrossi
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.